UNSPSC 51113502: Piposulfan

This classification denotes an alkylsulfonate compound with the molecular formula C12H22N2O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VY5DPN1TDU, chemically known as 1,4-dihydracryloylpiperazine dimethanesulfonate (ester) but more generally known as piposulfan, which bears US NIH Compound Identifier 17458. European Medicines Agency schedules Piposulfan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09878MIG. The term PIPOSULFAN is an International Non-Proprietary Name.

UNSPSC 51113502 Piposulfan is a Commodity code representing a specific pharmaceutical product. State and local governments purchasing under this code acquire piposulfan—a chemotherapy agent used in cancer treatment protocols—typically through pharmacy benefit programs, state health department formularies, and institutional healthcare procurement channels. The work being solicited involves pharmaceutical sourcing and supply chain management rather than manufacturing or compounding; state and local health agencies use this code to manage inventory, negotiate pricing, and ensure formulary compliance for patients receiving piposulfan-based cancer therapies.

State health agencies, particularly state health and human services commissions, drive activity under this code. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) in March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, a market-intelligence exercise that signals the state's interest in restructuring its pharmaceutical procurement approach to improve cost management and fulfillment efficiency outside traditional pharmacy benefit manager and group purchasing organization channels. The RFI sought vendor experience with direct contracting for self-insured employers and health plans, negotiated net pricing models, and outcomes-based agreements—indicating that state pharmacy benefit programs are actively exploring alternative supply models for specialty pharmaceuticals. The April 3, 2026 response deadline has passed. No additional state or local solicitations specifically for piposulfan appear in the recent opportunity record, suggesting modest procurement volume under this narrow Commodity code relative to broader pharmaceutical family codes.